Keuangan Vertex Pharmaceuticals (VRTX)
NASDAQ · Healthcare · Biotechnology · Karyawan: 6.400 · CEO: Reshma Kewalramani
- Harga
- $558,88 +3,50%
- Kapitalisasi pasar
- $142 M
- Nilai perusahaan
- $137 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-04
- Laporan berikutnya
- 2026-11-02 Estimasi EPS: $4,82
Pendapatan (TTM)$12,6 M+10,6% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)38,6%+4,2 poin vs tahun laluLaba operasional: $4,87 M
Laba bersih (TTM)$4,41 M+21,1% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$3,8 M+8,5% vs tahun laluCapex: $497 jt
EPS dilusian (TTM)$17,18+22,8% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$5,87 M+21,0% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $142 M EV $137 M
- Pendapatan
- $12,6 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +10% Konsensus FY2026
- Margin laba
- 34,9% Laba bersih / pendapatan, TTM
- P/E
- 32,3× Forward 29,8× (FY2026)
- P/S
- 11,2× Harga / penjualan, TTM
- EV / EBITDA
- 25,0× TTM
- Arus kas bebas
- $3,8 M 12 bulan terakhir
- Laba bersih
- $4,41 M 12 bulan terakhir
- Estimasi pendapatan
- $13,3 M Konsensus FY2026
- Laba
- 2026-11-02 Estimasi pendapatan: $3,42 M
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-03): pendapatan melampaui 3,2%, EPS sesuai ekspektasiPendapatan $3,33 M vs $3,23 M yang diharapkan (+3,2%); EPS $4,73 vs $4,74 (-0,2%).
- Pertumbuhan pendapatan menguat: 12,5% yoyPendapatan Q2 '26: $3,33 M, rata-rata empat kuartal sebelumnya: 10,4%.
- Margin operasional 38,6% (TTM), dibanding tahun lalu: +4,2 poinLaba operasional tumbuh 24,2%, pendapatan tumbuh 10,6%.
- Capex: 3,9% dari pendapatan (tahun lalu 3,0%)$497 jt diinvestasikan dalam 4 kuartal terakhir (+43,3% dibanding tahun sebelumnya). Arus kas bebas: $3,8 M = 86,2% dari laba bersih.
- $2,24 M dikembalikan ke pemegang saham = 59,0% dari arus kas bebasBuyback: $2,24 M (tahun lalu $1,54 M), dividen: $0, kompensasi saham: $689 jt (TTM).
- Jumlah saham dilusian turun dalam setahun: 1,2%Saham dilusian pada Q2 '26: 256 jt, setahun sebelumnya: 259 jt.
- Kas neto: $5,87 MKas + investasi jangka pendek: $7,85 M, utang termasuk sewa: $1,98 M; tahun lalu kas neto: $4,86 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $3,33 M | $2,96 M | +12,5% |
| Margin kotor | 85,3% | 86,3% | -0,9 poin |
| Laba operasional | $1,25 M | $1,15 M | +8,4% |
| Margin operasional | 37,4% | 38,8% | -1,4 poin |
| Laba bersih | $1,1 M | $1,03 M | +6,5% |
| EPS dilusian | $4,31 | $3,99 | +8,0% |
| Arus kas operasional | $1,13 M | $1,07 M | +4,9% |
| Capex | $112 jt | $146 jt | -23,0% |
| Arus kas bebas | $1,01 M | $927 jt | +9,3% |
| R&D | $994 jt | $978 jt | +1,6% |
| Kompensasi berbasis saham | $170 jt | $167 jt | +1,7% |
Dilaporkan vs konsensus
2026-08-03| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $3,33 M | $3,23 M | +3,2% |
| EPS (basis konsensus) | $4,73 | $4,74 | -0,2% |
Dari laporan 2026-08-03 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | $2,5 M | -2,1% | 77,8% | $10,1 M | -3,0% | |
| Manufactured Product, Other | $137 jt | -41,9% | 4,3% | $686 jt | -42,3% | |
| ALYFTREK | $574 jt | +265,8% | 17,9% | $1,63 M | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Non-US | $1,58 M | – | 34,2% | $8,49 M | – | |
| United States | $2,06 M | +12,5% | 44,6% | $7,9 M | +12,3% | |
| Europe | $978 jt | +7,3% | 21,2% | $3,65 M | +6,8% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $4,29 M
- Capex
- -$497 jt
- Buyback
- -$2,24 M
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- -$2,8 jt
- Kompensasi berbasis saham
- $689 jt
- Arus kas bebas
- $3,8 M
- Dikembalikan ke pemegang saham / FCF
- 59,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 32,3× | 26,2× 4 dari 5 tahun | 22,3× – 29,3× |
| EV / EBITDA | 25,0× | 56,7× | 14,5× – 207,4× |
| EV / Penjualan | 10,9× | 8,4× | 6,7× – 9,7× |
| Harga / FCF | 37,3× | 27,7× 4 dari 5 tahun | 18,8× – 36,3× |
| Harga / Nilai buku | 7,0× | 5,9× | 5,3× – 6,3× |
| Imbal hasil FCF | 2,7% | 2,9% | -0,8% – 5,3% |
| Imbal hasil modal yang diinvestasikan | 17,3% | 16,0% | 2,6% – 21,8% |
| Imbal hasil ekuitas | 23,3% | 17,1% | -3,3% – 23,9% |
Analis
Target konsensus $573,50 (+2,6%)
rentang $350,00 – $665,00 · peringkat Buy
Beli kuat0
Beli47
Tahan8
Jual1
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $13,3 M | +9,8% | $18,73 | +22,3% | 29,8× | 11 |
| FY2027 | $14,7 M | +10,6% | $21,08 | +12,5% | 26,5× | 13 |
| FY2028 | $16,5 M | +12,3% | $25,16 | +19,3% | 22,2× | 7 |
| FY2029 | $18,6 M | +12,7% | $29,90 | +18,8% | 18,7× | 2 |
| FY2030 | $20,5 M | +10,7% | $34,11 | +14,1% | 16,4× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 271 angka yang ditandai Vertex Pharmaceuticals Incorporated dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $430 jt | $442 jt | -2,9% | $462 jt | $413 jt | +11,8% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $2,13 M | $1,89 M | +12,7% | $2,05 M | $1,61 M | +27,6% |
| Accrued Liabilities, Current | $3,18 M | $3,27 M | -2,8% | $2,97 M | $2,79 M | +6,5% |
| Accrued Royalties, Current | $277 jt2025-12-31 | $271 jt | +2,1% | $277 jt | $271 jt | +2,1% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $48,5 jt | -$101 jt | +148,0% | -$15,9 jt | $128 jt | -112,4% |
| Additional Paid in Capital, Common Stock | $4,51 M | $5,99 M | -24,8% | $5,12 M | $6,67 M | -23,3% |
| Advertising Expense | – | – | – | $203 jt | $85,7 jt | +136,6% |
| Amortization of Intangible Assets | – | – | – | $20,2 jt | $20,2 jt | 0,0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $174 jt | $171 jt | +1,6% | $700 jt | $709 jt | -1,2% |
| Assets | $27,4 M | $24 M | +14,1% | $25,6 M | $22,5 M | +13,8% |
| Assets, Current | $12,5 M | $10,4 M | +20,3% | $11,2 M | $9,6 M | +16,7% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $400 rb | $900 rb | -55,6% | $2,1 jt | -$500 rb | +520,0% |
| Business Combination, Contingent Consideration, Liability | $79,6 jt | $80 jt | -0,5% | $79 jt | $76,9 jt | +2,7% |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $79 jt2025-12-31 | $76,9 jt | +2,7% | $79 jt | $76,9 jt | +2,7% |
| Capitalized Computer Software, Amortization | – | – | – | $31,2 jt | $25,2 jt | +23,8% |
| Capitalized Computer Software, Gross | $66,6 jt2025-12-31 | $62,6 jt | +6,4% | $66,6 jt | $62,6 jt | +6,4% |
| Cash and Cash Equivalents, at Carrying Value | $6,14 M | $4,97 M | +23,6% | $5,08 M | $4,57 M | +11,3% |
| Cash Flow Hedge Derivative Instrument Assets at Fair Value | $6,2 jt2025-12-31 | $130 jt | -95,2% | $6,2 jt | $130 jt | -95,2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $6,15 M | $4,98 M | +23,5% | $5,09 M | $4,57 M | +11,3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $649 jt | $297 jt | +118,9% | $516 jt | -$5,8 M | +108,9% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 500 jt | 500 jt | 0,0% | 500 jt | 500 jt | 0,0% |
| Common Stock, Shares, Issued | 253 jt | 256 jt | -1,1% | 254 jt | 257 jt | -1,1% |
| Common Stock, Shares, Outstanding | 253 jt | 256 jt | -1,1% | 254 jt | 257 jt | -1,1% |
| Common Stock, Value, Issued | $2,5 jt | $2,6 jt | -3,8% | $2,5 jt | $2,6 jt | -3,8% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $1,12 M | $864 jt | +30,1% | $3,81 M | -$394 jt | +1.068,1% |
| Contract with Customer, Liability | $157 jt | $147 jt | +6,9% | $172 jt | $207 jt | -16,9% |
| Contract with Customer, Liability, Revenue Recognized | – | – | – | $207 jt | $170 jt | +21,4% |
| Cost of Goods and Services Sold | $489 jt | $408 jt | +20,0% | $1,65 M | $1,53 M | +7,9% |
| Costs and Expenses | $2,09 M | $1,81 M | +15,1% | $7,83 M | $11,3 M | -30,4% |
| Current Federal Tax Expense (Benefit) | – | – | – | $679 jt | $705 jt | -3,7% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $486 jt | $310 jt | +56,8% |
| Current Income Tax Expense (Benefit) | – | – | – | $1,2 M | $1,13 M | +6,0% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $35,9 jt | $118 jt | -69,6% |
| Debt Securities, Available-for-sale | $7,49 M | – | – | $8,88 M2023-12-31 | $5,64 M | +57,5% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $7,5 jt | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $26,2 jt | $1,2 jt | +2.083,3% | $600 rb | $10,6 jt | -94,3% |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $7,5 M | – | – | – | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $100 rb2026-03-31 | $100 rb | 0,0% | $100 rb | $100 rb | 0,0% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | $8,4 jt2026-03-31 | $7,6 jt | +10,5% | $9,7 jt | $19,1 jt | -49,2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $99,6 jt | – | – | $2,2 jt2023-12-31 | $0 | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $5,69 M | – | – | $2,5 M2023-12-31 | $112 jt | +2.124,2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $1,7 M | – | – | $6,39 M2023-12-31 | $5,53 M | +15,5% |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $4,8 M | $816 jt | +488,2% | $632 jt | $2,2 M | -71,3% |
| Deferred Costs | $318 jt2025-12-31 | $279 jt | +14,0% | $318 jt | $279 jt | +14,0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$527 jt | -$439 jt | -20,1% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $38,3 jt | $139 jt | -72,4% |
| Deferred Income Tax Assets, Net | $3,01 M | $2,71 M | +11,0% | $2,9 M | $2,33 M | +24,3% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$511 jt | -$349 jt | -46,4% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$22,1 jt | -$48,7 jt | +54,6% |
| Deferred Tax Assets, Gross | $3,72 M2025-12-31 | $3,16 M | +17,8% | $3,72 M | $3,16 M | +17,8% |
| Deferred Tax Assets, in Process Research and Development | $1,92 M2025-12-31 | $1,4 M | +36,8% | $1,92 M | $1,4 M | +36,8% |
| Deferred Tax Assets, Net | $2,9 M2025-12-31 | $2,33 M | +24,3% | $2,9 M | $2,33 M | +24,3% |
| Deferred Tax Assets, Net of Valuation Allowance | $3,4 M2025-12-31 | $2,89 M | +17,6% | $3,4 M | $2,89 M | +17,6% |
| Deferred Tax Assets, Other | $234 jt2025-12-31 | $192 jt | +21,6% | $234 jt | $192 jt | +21,6% |
| Deferred Tax Assets, Tax Credit Carryforwards | $356 jt2025-12-31 | $298 jt | +19,3% | $356 jt | $298 jt | +19,3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $172 jt2025-12-31 | $164 jt | +4,6% | $172 jt | $164 jt | +4,6% |
| Deferred Tax Assets, Valuation Allowance | $326 jt2025-12-31 | $273 jt | +19,5% | $326 jt | $273 jt | +19,5% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01